On Friday, biopharmaceutical company AstraZeneca announced that it would resume the COVID-19 vaccine in the United States, adding at UW Health and the UW School of Medicine and Public Health.
On 6 September, 3 trials of the AstraZeneca COVID-19 vaccine in the United States were suspended due to an unknown spinal cord challenge encountered through a female trial volunteer in the UNITED Kingdom.
The FDA and an independent protective review committee completed a review of the participant’s undiagnosed disease and relative trial protection, which led to the announcement of UW Health on October 23 detailing the resumption of the trial in Madison, Wisconsin.
“It’s not very unusual to prevent clinical trials from being reviewed, but they don’t stand out on a global scale like this,” said Betsy Nugent, MSPH, CCRP, director of clinical research and director of clinical trial development and accreditation at the University of Washington. Faculty of Medicine and Public Health. ” We are very happy to continue these vital paintings and are grateful for the help of the community. “
William Hartman, assistant professor of anesthesiology and principal investigator of the clinical trial of the AstraZeneca COVID-19 vaccine, the importance of protection in the stages of vaccine progression.
“The United States has some of the strictest regulatory regulations in the world and has been very well researched to determine the quality of the vaccine. The formula is working. Only one in 20,000 patients worldwide developed an unexplained disease and the trial stopped,” Hartman said. “This deserves to give the public the security that the FDA and the independent review committee take into account the public interest. You must be sure that vaccines are for everyone. This is not a race to produce the fastest vaccine, they are clinical trials to locate the right vaccine.
UW is one of hundreds of clinics across the country that have been selected to participate in the vaccine trial. The university hospital sought to recruit another 1,600 people within 8 weeks, according to a press release of August 31 of the Faculty of UW. Medicine and Public Health.
During the clinical trial, volunteer participants were randomly assigned to one of two: one who won two placebo injections and one who won two injections of AZD1222, the experimental vaccine. Two-thirds of the test subjects won the experimental vaccine.
“UW Health and SMPH pride themselves on being at the forefront of localization and effective responses to this global pandemic,” Nugent said after the clinical trial. “Our entire team has been working diligently for months to bring this vital clinical trial to our state, and Wisconsin residents now have the opportunity to participate in crisis resolution. “
Please note that all comments may be in The Daily Cardinal.